| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	 
																	 
																	 
																	The "Jimmy Kimmel Live" drama coincided with reports of tit-for-tat maneuvering between the FCC and corporations desper...
 
																	
 
																	Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people s...
 
																	Maxim Group analyst Michael Okunewitch downgrades Anebulo Pharmaceuticals (NASDAQ:ANEB) from Buy to Hold.
 
																	
